Alkermes Announces Initiation of First Clinical Study for a Four-Week Long-Acting Injectable Formulation of Risperidone

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), has initiated a phase 1 study of a four-week long-acting injectable formulation of risperidone for the treatment of schizophrenia. The single-dose, open-label study is designed to assess the pharmacokinetics, safety and tolerability of a gluteal injection of this risperidone formulation in approximately 26 patients diagnosed with chronic, stable schizophrenia. A two-week long-acting injectable formulation of risperidone, marketed as RISPERDAL® CONSTA® ((risperidone) Long-Acting Injection), is commercially available in more than 60 countries.

Back to news